Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
Arcturus Therapeutics Holdings (Nasdaq: ARCT) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company focuses on mRNA medicines targeting infectious diseases and rare liver and respiratory diseases. Arcturus has a diverse pipeline including vaccines for SARS-CoV-2 and influenza, as well as programs for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis.
- Diverse pipeline includes mRNA vaccines for SARS-CoV-2 and influenza.
- Collaborations with notable companies like Janssen Pharmaceuticals and Takeda.
- None.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the first quarter ended March, 31, 2021 after the market close on Monday May 10, and will also host a conference call and webcast at 4:30 pm Eastern Time on May 10, 2021.
Monday, May 10th @ 4:30 p.m. ET |
|||
Domestic: |
877-256-4295 |
||
International: |
212-231-2927 |
||
Conference ID: |
21993793 |
||
Webcast: |
|||
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005351/en/
FAQ
When will Arcturus Therapeutics release its Q1 2021 financial results?
What time is the Arcturus conference call on May 10, 2021?
What is the focus of Arcturus Therapeutics?
